# Nivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung Cancer

> **NCT02846792** · PHASE1,PHASE2 · TERMINATED · sponsor: **University of Washington** · enrollment: 5 (actual)

## Conditions studied

- ALK Gene Translocation
- EGFR Activating Mutation
- Recurrent Non-Small Cell Lung Carcinoma
- ROS1 Gene Translocation
- Stage IIIB Non-Small Cell Lung Cancer AJCC v7
- Stage IV Non-Small Cell Lung Cancer AJCC v7

## Interventions

- **BIOLOGICAL:** Nivolumab
- **DRUG:** Plinabulin

## Key facts

- **NCT ID:** NCT02846792
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-06-14
- **Primary completion:** 2018-07-12
- **Final completion:** 2018-08-16
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Immunotherapy approved for NSCLC in the first line setting
- **Last updated:** 2019-03-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02846792

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02846792, "Nivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02846792. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*